Is CNMD a good stock to buy right now?

Based on our 6-factor quantitative model, CONMED Corp (CNMD) receives a "Reduce" rating with a composite score of 45.9/100. It is ranked #2,215 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 69/100, Momentum 25/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for CNMD?

CONMED Corp (CNMD) has a "Reduce" rating and 2-star score. The composite score of 45.9 ranks it #2,215 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is CNMD in?

CONMED Corp operates in the Healthcare sector (Medical Equipment industry) with a market cap of $1.10 billion. It is classified as a small-cap stock.

Does CNMD pay a dividend?

Yes, CNMD pays a dividend with a current yield of 1.70%. For every $1,000 invested, you would receive approximately $17.00 in annual dividend income.

What is CNMD's P/E ratio?

CNMD has a trailing P/E ratio of 13.43x. The Healthcare sector average is 23.6x. This below-average P/E may indicate the stock is undervalued.

How profitable is CNMD?

CNMD's quality factor score is 50/100. Gross margin: 54.0%. ROE: 7.7% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is CNMD valued compared to peers?

CNMD's value factor score is 69/100 (higher = cheaper). Key multiples: P/E 13.4x, EV/EBITDA 8.1x. The stock appears attractively valued versus peers.

What is CNMD's debt level?

CNMD's debt-to-equity ratio is 125%. Sector average: 32%. Moderate leverage is normal for established companies.

CNMD has a beta of 1.05, meaning it tracks the market. Stability score: 54/100.

Does CNMD have high short interest?

CNMD's short interest factor score is 56/100 (higher = less short selling). Moderate short interest.

CNMD Stock Analysis: Top Small-Cap Reduce (Score 45.9/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
CNMD	+0.93%	+3.94%	-7.44%	-9.04%	-34.96%	-	-	-
Industry Proxy XLV	-0.23%	+1.08%	-2.21%	-3.53%	+7.62%	-	-	-
U.S. Market SPY	+0.58%	+3.77%	+1.12%	-0.29%	+23.93%	-	-	-
Alpha vs Market	+0.35%	+0.18%	-8.56%	-8.74%	-58.89%	-	-	-
Alpha vs Sector	+1.16%	+2.86%	-5.24%	-5.51%	-42.58%	-	-	-

Metric	CNMD	Benchmark
P/E Ratio	13.4x	-43%
EV/EBITDA	8.1x	+28%
Price / Book	1.0x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
CNMD CONMED Corp	46	50	69	25	13.4x	7.7%	54.0%	6.1%	1.8%	125.0x	$1.1B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.5%	0.5%	0.6%	0.5%	0.5%	0.6%	0.5%	0.5%	0.5%	0.5%	0.5%
Operating Margin %	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%
EBITDA Margin %	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.2%	0.2%	0.2%	0.1%	0.1%
Net Margin %	0.1%	0.0%	0.1%	0.1%	-0.1%	0.1%	0.0%	0.0%	0.0%	0.1%	0.0%
FCF Margin %	1.5%	-	-	-	-	-	6.0%	7.9%	6.8%	6.6%	3.1%
ROE %	0.1%	0.0%	0.1%	0.1%	-0.1%	0.1%	0.0%	0.0%	0.1%	0.1%	0.0%
ROA %	0.0%	0.0%	0.1%	0.0%	-0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ROIC %	5.6%	7.8%	16.4%	11.4%	7.4%	11.0%	2.5%	4.3%	5.1%	3.4%	2.8%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.5%

0.6%

0.5%

0.6%

0.5%

Operating Margin %

0.1%

0.2%

0.1%

0.0%

EBITDA Margin %

0.1%

0.2%

0.1%

0.2%

0.1%

Net Margin %

0.1%

0.0%

0.1%

-0.1%

0.1%

0.0%

0.1%

0.0%

FCF Margin %

1.5%

6.0%

7.9%

6.8%

6.6%

3.1%

ROE %

0.1%

0.0%

0.1%

-0.1%

0.1%

0.0%

0.1%

0.0%

ROA %

0.0%

0.1%

0.0%

-0.0%

0.0%

ROIC %

5.6%

7.8%

16.4%

11.4%

7.4%

11.0%

2.5%

4.3%

5.1%

3.4%

2.8%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$1.3B	$1.4B	$1.3B	$1.2B	$1.0B	$1.0B	$862M	$955M	$860M	$796M	$764M	$719M
	—	$624M	$574M	$568M	$474M	$443M	—	—	—	—	—	—
	$711M	$750M	$733M	$676M	$571M	$568M	$460M	$525M	$469M	$431M	$408M	$382M
Gross Margin	54.0%	54.6%	56.1%	54.3%	54.6%	56.2%	53.4%	54.9%	54.6%	54.1%	53.5%	53.1%
	—	$592M	$478M	$503M	$454M	$415M	—	—	—	—	—	—
Research & Development	—	$56M	$54M	$53M	$47M	$44M	$40M	$45M	$42M	$32M	$32M	$27M
Depreciation	—	—	—	—	—	—	$86M	$84M	$62M	$59M	$55M	$44M
Total Operating Expenses	—	$648M	$533M	$556M	$501M	$458M	—	—	—	—	—	—
	$132M	$103M	$200M	$121M	$70M	$110M	$46M	$79M	$71M	$47M	$38M	$51M
EBIT	$132M	$103M	$200M	$121M	$70M	$110M	$46M	$79M	$71M	$47M	$38M	$51M
EBITDA	$132M	$103M	$200M	$121M	$70M	$110M	$132M	$158M	$133M	$105M	$90M	$95M
Operating Margin	10.1%	7.5%	15.3%	9.7%	6.7%	10.9%	5.3%	8.3%	8.3%	5.9%	4.9%	7.1%
EBITDA Margin	10.0%	7.5%	15.3%	9.7%	6.7%	10.9%	15.3%	16.5%	15.5%	13.2%	11.8%	13.2%
	—	$31M	$37M	$40M	$29M	$35M	$44M	$43M	$21M	$18M	$15M	$6M
	—	$71M	$163M	$81M	-$71M	$73M	—	—	—	—	—	—
Income Tax Expense	—	$24M	$31M	$16M	$10M	$11M	-$8M	$3M	$10M	-$27M	$5M	$15M
	$79M	$47M	$132M	$64M	-$81M	$63M	$10M	$29M	$41M	$55M	$15M	$30M
Net Margin	6.1%	3.4%	10.1%	5.2%	-7.7%	6.2%	1.1%	3.0%	4.8%	7.0%	1.9%	4.2%
	$1.52	$1.52	$4.29	$2.10	$-2.68	$2.14	$0.33	$1.01	$1.45	$1.99	$0.53	$1.10
Diluted EPS	$1.52	$1.51	$4.25	$2.04	$-2.68	$1.94	$0.33	$1.01	$1.45	$1.99	$0.53	$1.10
Weighted Avg Basic	—	31M	31M	31M	30M	29M	—	—	—	—	—	—
Weighted Avg Diluted	—	31M	31M	32M	30M	32M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$1.3B

$1.4B

$1.3B

$1.2B

$1.0B

$862M

$955M

$860M

$796M

$764M

$719M

—

$624M

$574M

$568M

$474M

$443M

—

$711M

$750M

$733M

$676M

$571M

$568M

$460M

$525M

$469M

$431M

$408M

$382M

Gross Margin

54.0%

54.6%

56.1%

54.3%

54.6%

56.2%

53.4%

54.9%

54.6%

54.1%

53.5%

53.1%

—

$592M

$478M

$503M

$454M

$415M

—

Research & Development

—

$56M

$54M

$53M

$47M

$44M

$40M

$45M

$42M

$32M

$27M

Depreciation

—

$86M

$84M

$62M

$59M

$55M

$44M

Total Operating Expenses

—

$648M

$533M

$556M

$501M

$458M

—

$132M

$103M

$200M

$121M

$70M

$110M

$46M

$79M

$71M

$47M

$38M

$51M

EBIT

$132M

$103M

$200M

$121M

$70M

$110M

$46M

$79M

$71M

$47M

$38M

$51M

EBITDA

$132M

$103M

$200M

$121M

$70M

$110M

$132M

$158M

$133M

$105M

$90M

$95M

Operating Margin

10.1%

7.5%

15.3%

9.7%

6.7%

10.9%

5.3%

8.3%

5.9%

4.9%

7.1%

EBITDA Margin

10.0%

7.5%

15.3%

9.7%

6.7%

10.9%

15.3%

16.5%

15.5%

13.2%

11.8%

13.2%

—

$31M

$37M

$40M

$29M

$35M

$44M

$43M

$21M

$18M

$15M

$6M

—

$71M

$163M

$81M

-$71M

$73M

—

Income Tax Expense

—

$24M

$31M

$16M

$10M

$11M

-$8M

$3M

$10M

-$27M

$5M

$15M

$79M

$47M

$132M

$64M

-$81M

$63M

$10M

$29M

$41M

$55M

$15M

$30M

Net Margin

6.1%

3.4%

10.1%

5.2%

-7.7%

6.2%

1.1%

3.0%

4.8%

7.0%

1.9%

4.2%

$1.52

$4.29

$2.10

$-2.68

$2.14

$0.33

$1.01

$1.45

$1.99

$0.53

$1.10

Diluted EPS

$1.52

$1.51

$4.25

$2.04

$-2.68

$1.94

$0.33

$1.01

$1.45

$1.99

$0.53

$1.10

Weighted Avg Basic

—

31M

30M

29M

—

Weighted Avg Diluted

—

31M

32M

30M

32M

—

CONMED Corp (CNMD) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does CONMED Corp Do?

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida. CONMED Corp (CNMD) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Curt R. Hartman and employs approximately 4,100 people, headquartered in Utica, Florida. With a market capitalization of $1.1B, CNMD is one of the notable companies in the Healthcare sector.

CONMED Corp (CNMD) Stock Rating — Reduce (April 2026)

As of April 2026, CONMED Corp receives a Reduce rating with a composite score of 45.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CNMD ranks #2,215 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CONMED Corp ranks #258 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CNMD Stock Price and 52-Week Range

CONMED Corp (CNMD) currently trades at $36.93. The 52-week high for CNMD is $61.25, which means the stock is currently trading -39.7% from its annual peak. The 52-week low is $35.37, putting the stock 4.4% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is CNMD Overvalued or Undervalued? — Valuation Analysis

CONMED Corp (CNMD) carries a value factor score of 69/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 13.43x, compared to the Healthcare sector average of 23.63x — a discount of 43%. The price-to-book ratio stands at 1.03x, versus the sector average of 2.75x. The price-to-sales ratio is 0.81x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, CNMD trades at 8.09x EV/EBITDA, versus 6.34x for the sector.

Overall, CNMD's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

CONMED Corp Profitability — ROE, Margins, and Quality Score

CONMED Corp (CNMD) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 7.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 3.4% versus the sector average of -33.1%.

On a margin basis, CONMED Corp reports gross margins of 54.0%, compared to 71.5% for the sector. The operating margin is 10.1% (sector: -66.1%). Net profit margin stands at 6.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 1.8% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

CNMD Debt, Balance Sheet, and Financial Health

CONMED Corp has a debt-to-equity ratio of 125.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.14x, indicating strong short-term liquidity. Total debt on the balance sheet is $854M. Cash and equivalents stand at $39M.

CNMD has a beta of 1.05, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for CONMED Corp is 54/100, reflecting average volatility within the normal range for its sector.

CONMED Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, CONMED Corp reported revenue of $1.32B and earnings per share (EPS) of $1.52. Net income for the quarter was $79M. Gross margin was 54.0%. Operating income came in at $132M.

In FY 2025, CONMED Corp reported revenue of $1.37B and earnings per share (EPS) of $1.52. Net income for the quarter was $47M. Gross margin was 54.6%. Revenue grew 5.2% year-over-year compared to FY 2024. Operating income came in at $103M.

In Q3 2025, CONMED Corp reported revenue of $338M and earnings per share (EPS) of $0.09. Net income for the quarter was $3M. Gross margin was 49.2%. Revenue grew 6.7% year-over-year compared to Q3 2024. Operating income came in at $12M.

In Q2 2025, CONMED Corp reported revenue of $342M and earnings per share (EPS) of $0.69. Net income for the quarter was $21M. Gross margin was 55.0%. Revenue grew 3.1% year-over-year compared to Q2 2024. Operating income came in at $38M.

Over the past 8 quarters, CONMED Corp has demonstrated a growth trajectory, with revenue expanding from $332M to $1.32B. Investors analyzing CNMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CNMD Dividend Yield and Income Analysis

CONMED Corp (CNMD) currently pays a dividend yield of 1.7%. At this yield, a $10,000 investment in CNMD stock would generate approximately $$170.00 in annual dividend income. The net margin of 6.1% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.

CNMD Momentum and Technical Analysis Profile

CONMED Corp (CNMD) has a momentum factor score of 25/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 33/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.

CNMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CONMED Corp (CNMD) ranks #258 out of 838 stocks based on the Blank Capital composite score. This places CNMD in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CNMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CNMD vs S&P 500 (SPY) comparison to assess how CONMED Corp stacks up against the broader market across all factor dimensions.

CNMD Next Earnings Date

No upcoming earnings date has been announced for CONMED Corp (CNMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CNMD? — Investment Thesis Summary

The quantitative profile for CONMED Corp suggests caution. The value score of 69/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 25/100, a headwind for near-term performance.

In summary, CONMED Corp (CNMD) earns a Reduce rating with a composite score of 45.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CNMD stock.

Related Resources for CNMD Investors

Explore more research and tools: CNMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CNMD head-to-head with peers: CNMD vs AZN, CNMD vs SLGL, CNMD vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Q4 Earnings Highs And Lows: CONMED (NYSE:CNMD) Vs The Rest Of The Surgical Equipment & Consumables - Diversified Stocks

Here's Why You Should Retain CONMED Stock in Your Portfolio Now

Orthopedic Power Tools Market to Reach US$ 2.6 Billion by 2033 Expands Amid Surgical Innovation and Rising Procedure Volumes

3 Small-Cap Stocks Walking a Fine Line

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

CONMED Corp (CNMD) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does CONMED Corp Do?

CONMED Corp (CNMD) Stock Rating — Reduce (April 2026)

CNMD Stock Price and 52-Week Range

Is CNMD Overvalued or Undervalued? — Valuation Analysis

CONMED Corp Profitability — ROE, Margins, and Quality Score

CNMD Debt, Balance Sheet, and Financial Health

CONMED Corp Revenue and Earnings History — Quarterly Trend

CNMD Dividend Yield and Income Analysis

CNMD Momentum and Technical Analysis Profile

CNMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

CNMD Next Earnings Date

Should You Buy CNMD? — Investment Thesis Summary

Related Resources for CNMD Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Q4 Earnings Highs And Lows: CONMED (NYSE:CNMD) Vs The Rest Of The Surgical Equipment & Consumables - Diversified Stocks

Here's Why You Should Retain CONMED Stock in Your Portfolio Now

Orthopedic Power Tools Market to Reach US$ 2.6 Billion by 2033 Expands Amid Surgical Innovation and Rising Procedure Volumes

3 Small-Cap Stocks Walking a Fine Line